SCHOTT Pharma AG & Co. KGaA (SHTPY)
| Market Cap | 2.77B -33.0% |
| Revenue (ttm) | 1.14B +1.7% |
| Net Income | 164.32M -3.9% |
| EPS | 1.08 -5.1% |
| Shares Out | n/a |
| PE Ratio | 16.87 |
| Forward PE | 15.30 |
| Dividend | 0.03 (0.65%) |
| Ex-Dividend Date | Feb 5, 2026 |
| Volume | 100 |
| Average Volume | 138 |
| Open | 4.370 |
| Previous Close | 4.500 |
| Day's Range | 4.370 - 4.370 |
| 52-Week Range | 4.370 - 7.650 |
| Beta | 0.89 |
| RSI | n/a |
| Earnings Date | May 13, 2026 |
About SHTPY
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold application... [Read more]
Financial Performance
In fiscal year 2025, SHTPY's revenue was 986.21 million, an increase of 3.04% compared to the previous year's 957.09 million. Earnings were 146.45 million, a decrease of -2.16%.
Financial numbers in EUR Financial StatementsNews
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q2 2026
H1 2026 saw resilient revenue and EBITDA growth, led by DCS and high-value solutions, while DDS faced temporary headwinds due to a one-off impairment. Guidance for FY 2026 is reaffirmed, with strong order book visibility and strategic investments supporting future growth.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue up 4.8% at constant currencies and EBITDA margin rise to 27.1%, driven by strong demand for high-value solutions. Guidance for FY 2026 is maintained, with expected revenue growth of 2%-5% and continued investment in capacity expansion.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q4 2025
Revenue grew 3% to EUR 986 million in 2025, with high-value solutions at 57% of sales and EBITDA margin up to 28.4%. 2026 guidance anticipates 2%-5% revenue growth and a 27% EBITDA margin, with GLP-1 and specialty vials as key drivers amid lower mRNA and vaccine demand.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q3 2025
Q3 revenue grew 3% year-over-year to €256 million, with EBITDA up 11% to €83 million and a record 31.7% margin, driven by high-value solutions. FY2025 guidance is for 6% organic revenue growth and a 28% EBITDA margin, with continued investment in capacity and innovation.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q2 2025
Q2 2025 saw revenues rise 8% year-on-year to EUR 252 million, with EBITDA up 63% and a margin of 28.6%, driven by strong HVS demand. Full-year guidance is maintained amid market volatility, with CapEx reduced and limited tariff impact expected.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q1 2025
Q1 2025 saw stable revenues of EUR 230 million, with strong HVS demand and robust order intake in vials, especially in EMEA and North America. EBITDA margin was 26.3% at constant currencies, and full-year guidance for high single-digit revenue growth and stable margins is confirmed.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q4 2024
Delivered strong revenue and profitability in 2024, with high-value solutions driving growth and new long-term contracts signed, especially in GLP-1. 2025 guidance calls for high single-digit revenue growth, stable margins, and back-end loaded performance as new capacities ramp up.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q3 2024
Q3 saw record revenue and EBITDA growth, driven by strong DDS demand and capacity expansion, with HVS share reaching 53%. Full-year revenue guidance was raised to 11%-13%, and robust market trends in GLP-1, mRNA, and ADCs support a positive outlook.